1
|
Teixeira R, Stefanelli A, Pilon A, Warmers R, Fontrodona X, Romero I, Costa PJ, Villa de Brito MJ, Hudec X, Pirker C, Türck S, Antunes AMM, Kowol CR, Ott I, Brozovic A, Sombke A, Eckhard M, Tomaz AI, Heffeter P, Valente A. Paraptotic Cell Death as an Unprecedented Mode of Action Observed for New Bipyridine-Silver(I) Compounds Bearing Phosphane Coligands. J Med Chem 2024; 67:6081-6098. [PMID: 38401050 PMCID: PMC11056982 DOI: 10.1021/acs.jmedchem.3c01036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 01/20/2024] [Accepted: 02/12/2024] [Indexed: 02/26/2024]
Abstract
In this work, we investigated the anticancer activity of several novel silver(I) 2,2'-bipyridine complexes containing either triphenylphosphane (PPh3) or 1,2-bis(diphenylphosphino)ethane (dppe) ligands. All compounds were characterized by diverse analytical methods including ESI-MS spectrometry; NMR, UV-vis, and FTIR spectroscopies; and elemental analysis. Moreover, several compounds were also studied by X-ray single-crystal diffraction. Subsequently, the compounds were investigated for their anticancer activity against drug-resistant and -sensitive cancer cells. Noteworthily, neither carboplatin and oxaliplatin resistance nor p53 deletion impacted on their anticancer efficacy. MES-OV cells displayed exceptional hypersensitivity to the dppe-containing drugs. This effect was not based on thioredoxin reductase inhibition, enhanced drug uptake, or apoptosis induction. In contrast, dppe silver drugs induced paraptosis, a novel recently described form of programmed cell death. Together with the good tumor specificity of this compound's class, this work suggests that dppe-containing silver complexes could be interesting drug candidates for the treatment of resistant ovarian cancer.
Collapse
Affiliation(s)
- Ricardo
G. Teixeira
- Centro
de Química Estrutural, Institute of Molecular Sciences, Departamento
de Química e Bioquímica, Faculdade
de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - Alessia Stefanelli
- Center
for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna 1090, Austria
| | - Adhan Pilon
- Centro
de Química Estrutural, Institute of Molecular Sciences, Departamento
de Química e Bioquímica, Faculdade
de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - Rebecca Warmers
- Center
for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna 1090, Austria
| | - Xavier Fontrodona
- Departament
de Química and Serveis Tècnics de Recerca, Universitat de Girona, Campus de Montilivi, Girona 17071, Spain
| | - Isabel Romero
- Departament
de Química and Serveis Tècnics de Recerca, Universitat de Girona, Campus de Montilivi, Girona 17071, Spain
| | - Paulo J. Costa
- BioISI
- Instituto de Biosistemas e Ciências Integrativas, Faculdade de Ciências, Universidade de Lisboa, Lisboa 1749-016, Portugal
| | - Maria J. Villa de Brito
- Centro
de Química Estrutural, Institute of Molecular Sciences, Departamento
de Química e Bioquímica, Faculdade
de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - Xenia Hudec
- Center
for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna 1090, Austria
| | - Christine Pirker
- Center
for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna 1090, Austria
| | - Sebastian Türck
- Institute
of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstr. 55, Braunschweig 38106, Germany
| | - Alexandra M. M. Antunes
- Centro de
Química Estrutural (CQE), Institute of Molecular Sciences,
Departamento de Engenharia Química, Instituto Superior Técnico
(IST), Universidade de Lisboa, Av Rovisco Pais 1, Lisboa 1049-001, Portugal
| | - Christian R. Kowol
- Institute
of Inorganic Chemistry, Faculty of Chemistry,
University of Vienna, Waehringerstrasse 42, Vienna 1090, Austria
| | - Ingo Ott
- Institute
of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstr. 55, Braunschweig 38106, Germany
| | - Anamaria Brozovic
- Division
of Molecular Biology, Ruđer Bošković
Institute, Bijenička
cesta 54,Zagreb 10000, Croatia
| | - Andy Sombke
- Center
for Anatomy and Cell Biology, Cell and Developmental Biology, Medical University of Vienna, Schwarzspanierstraße 17, Vienna 1090, Austria
| | - Margret Eckhard
- Center
for Anatomy and Cell Biology, Cell and Developmental Biology, Medical University of Vienna, Schwarzspanierstraße 17, Vienna 1090, Austria
| | - Ana Isabel Tomaz
- Centro
de Química Estrutural, Institute of Molecular Sciences, Departamento
de Química e Bioquímica, Faculdade
de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| | - Petra Heffeter
- Center
for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna 1090, Austria
| | - Andreia Valente
- Centro
de Química Estrutural, Institute of Molecular Sciences, Departamento
de Química e Bioquímica, Faculdade
de Ciências, Universidade de Lisboa, Campo Grande, Lisboa 1749-016, Portugal
| |
Collapse
|
2
|
Lorusso D, Daniele G. First line ovarian cancer treatment: Scanning the horizon. Crit Rev Oncol Hematol 2021; 160:103297. [PMID: 33684501 DOI: 10.1016/j.critrevonc.2021.103297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Accepted: 03/01/2021] [Indexed: 11/25/2022] Open
Affiliation(s)
- D Lorusso
- Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy.
| | - G Daniele
- Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| |
Collapse
|
3
|
Lorusso D, Ceni V, Muratore M, Salutari V, Nero C, Pietragalla A, Ciccarone F, Carbone V, Daniele G, Scambia G. Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. Expert Opin Emerg Drugs 2020; 25:445-453. [PMID: 33040627 DOI: 10.1080/14728214.2020.1836155] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
INTRODUCTION In recent years, ovarian cancer (OC) treatment has been enriched with many new target therapies, most of all antiangiogenic drugs and PARP inhibitors (PARPis), which have literally changed the natural history of the disease. The impressive results of immunotherapy in other malignancies, mainly melanoma and lung cancer, and the good signals of activity in gynecological neoplasms like cervical and microsatellite instable (MSI-H) endometrial cancer, opened the space to the introduction of immune-stimulatory drugs in ovarian cancer. AREA COVERED The goal of this article is to summarize the newest evidence on the use of immune check point inhibitors in OC trying to explain why, at present, this strategy has failed to improve clinical outcome and focusing on the possible strategies to overcome treatment failure. EXPERT OPINION Although numerous trials have been undertaken, only scanty results have been obtained so far with immune check-point inhibitors (ICIs) in OC either when used as single agents or in combination with antiangiogenic therapy and ongoing trials are exploring the association of ICIs with PARPis and other ICIs. A better knowledge of predictive biomarkers of response and mechanisms of immunotherapy resistance, will help in identifying the most appropriate population to treat with ICIs.
Collapse
Affiliation(s)
- Domenica Lorusso
- Scientific Directorate Fondazione Policlinico Universitario A Gemelli IRCCS , Rome, Italy.,Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli , Rome, Italy
| | - Valentina Ceni
- Department of Gynecology and Obstetrics, University of Parma, Via A. Gramsci , Parma, Italy.,Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli , Rome, Italy
| | - Margherita Muratore
- Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli , Rome, Italy.,Department of Medical Oncology, University of Naples Federico II, Via S.Pansini , Naples, Italy
| | - Vanda Salutari
- Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli , Rome, Italy
| | - Camilla Nero
- Scientific Directorate Fondazione Policlinico Universitario A Gemelli IRCCS , Rome, Italy
| | - Antonella Pietragalla
- Scientific Directorate Fondazione Policlinico Universitario A Gemelli IRCCS , Rome, Italy
| | - Francesca Ciccarone
- Scientific Directorate Fondazione Policlinico Universitario A Gemelli IRCCS , Rome, Italy
| | - Vittoria Carbone
- Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli , Rome, Italy
| | - Gennaro Daniele
- Scientific Directorate Fondazione Policlinico Universitario A Gemelli IRCCS , Rome, Italy
| | - Giovanni Scambia
- Scientific Directorate Fondazione Policlinico Universitario A Gemelli IRCCS , Rome, Italy.,Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli , Rome, Italy
| |
Collapse
|